华泰柏瑞生物医药混合C(010031)资产负债表
| |
2025-12-31 |
2025-06-30 |
2024-12-31 |
2024-06-30 |
| 资产 |
| 银行存款 |
- |
- |
- |
- |
| 结算备付金 |
1,912,545.08 |
1,171,119.28 |
1,408,963.22 |
1,309,929.40 |
| 存出保证金 |
195,412.66 |
220,336.38 |
222,496.70 |
191,687.67 |
| 交易性金融资产 |
590,150,109.22 |
671,362,251.23 |
427,361,580.24 |
427,415,651.82 |
| 其中:股票投资 |
590,150,109.22 |
671,362,251.23 |
427,361,580.24 |
427,415,651.82 |
| 债券投资 |
- |
- |
- |
- |
| 资产支持证券投资 |
- |
- |
- |
- |
| 衍生金融资产 |
- |
- |
- |
- |
| 买入返售金融资产 |
- |
- |
- |
- |
| 应收证券清算款 |
43,439,410.51 |
6,404,311.18 |
- |
3,877,167.60 |
| 应收利息 |
- |
- |
- |
- |
| 应收股利 |
- |
- |
- |
- |
| 应收申购款 |
721,428.22 |
450,503.82 |
112,754.17 |
192,540.65 |
| 其他资产 |
- |
- |
- |
- |
| 资产总计 |
681,752,421.27 |
721,789,941.68 |
467,058,767.20 |
499,920,061.69 |
| 负 债 |
| 短期借款 |
- |
- |
- |
- |
| 交易性金融负债 |
- |
- |
- |
- |
| 衍生金融负债 |
- |
- |
- |
- |
| 卖出回购金融资产款 |
- |
- |
- |
- |
| 应付证券清算款 |
- |
5,659,933.51 |
3,278,555.26 |
1,051,238.13 |
| 应付赎回款 |
54,002,717.06 |
7,177,282.04 |
1,061,146.11 |
225,555.90 |
| 应付管理人报酬 |
731,761.82 |
732,007.51 |
484,710.96 |
480,681.40 |
| 应付托管费 |
121,960.30 |
122,001.23 |
80,785.15 |
80,113.59 |
| 应付销售服务费 |
215,293.58 |
201,585.58 |
44,589.84 |
27,671.65 |
| 应付交易费用 |
- |
- |
- |
- |
| 应交税费 |
- |
- |
- |
- |
| 应付利息 |
- |
- |
- |
- |
| 应付利润 |
- |
- |
- |
- |
| 其他负债 |
991,483.49 |
665,828.41 |
685,205.69 |
1,245,046.30 |
| 负债合计 |
56,063,216.25 |
14,558,638.28 |
5,634,993.01 |
3,110,306.97 |
| 所有者权益 |
| 实收基金 |
237,566,619.21 |
261,146,033.78 |
228,026,129.06 |
248,311,186.82 |
| 未分配利润 |
388,122,585.81 |
446,085,269.62 |
233,397,645.13 |
248,498,567.90 |
| 所有者权益合计 |
625,689,205.02 |
707,231,303.40 |
461,423,774.19 |
496,809,754.72 |
| 负债及所有者权益总计 |
681,752,421.27 |
721,789,941.68 |
467,058,767.20 |
499,920,061.69 |
欢迎访问证券之星!请点此与我们联系 版权所有: Copyright © 1996-年